{'fraction_non_alphanumeric': 0.03798670465337132, 'fraction_numerical': 0.014719848053181387, 'mean_word_length': 5.384848484848485, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clotrimazole inhibits smooth muscle cell proliferation and has a vasodilator effect on resistance arteries

Abstract— Clotrimazole (CLT) is a drug known to interfere with cellular calcium homeostasis, which in turn is reported to intervene in cell proliferation and in the reactivity of small blood vessels. Experiments were designed to test the influence of CLT on the proliferative and vasorelaxant effect of bradykinin (BK) and on calcium homeostasis in smooth muscle cells (SMC). To this purpose two model systems were employed: (i) cultured human smooth muscle cells (HSMC), and (ii) isolated resistance arteries maintained in an organ bath. The effect of various concentrations of CLT (2–15 μM) on BK‐induced proliferation of HSMC was quantitated by spectrometry following [3H]‐thymidine incorporation, and intracellular calcium [Ca2+]i was determined by spectrofluorimetry using Fura 2‐AM assay. In other experiments the roles of BK receptor (AB2) and of thapsigargin were assessed. The reactivity of the resistance arteries was measured by the myograph technique, and the effects of BK, CLT, and NO synthase blocker, L‐NAME were evaluated. The results showed that 10 μM CLT: (i) inhibits the BK‐induced proliferation of HSMC by 45–50%; (ii) prevents the rise of[Ca2+]i induced by BK (120.8 ± 12.4 nM vs. 235.8 ± 34.1 nM), an effect similar to that of “classic” L‐type calcium channels blockers; (iii) reduces the release of Ca2+entry induced by thapsigargin suggesting a possible inhibition of the capacitative Ca2+entry. Organ bath assays showed that CLT enhanced the BK‐induced relaxation of the resistance arteries by an endothelium NO‐independent pathway. Together, these data suggest that the mechanism of action of CLT on SMC implies mainly a modification of intracellular calcium homeostasis, with a minor contribution of BK B2 receptors. These new distinctive features of CLT effects suggest the potential use of this drug in the therapy of cardiovascular diseases associated with SMC increased proliferation and impeded relaxation in small arteries, such as atherosclerosis and restenosis.